Onyx Studio Sessions: Fabian Gerlinghaus, CEO, Cellares
Can Cellares bring down the cost of some of the most expensive new therapies on the market?
Published 14 Jan 2025
Follow Onyx
LinkedIn Read us in Fortune Subscribe
Onyx @ Union Square: Mike Exton, CEO, Lexicon Pharmaceuticals
Lexicon's latest drug for obesity and weight management has a novel mechanism and is backed by Novo Nordisk.
Published 14 Jan 2025
Onyx @ Union Square: Shankar Musunuri, CEO, Ocugen
What if the key to curing blindness wasn't targeting individual genes, but entire genetic networks?
Published 13 Jan 2025
Is neuromodulation the breakthrough that Alzheimer's has been waiting for?
Sinaptica's precision neuromodulation combines TMS and EEG to target memory networks, offering new hope in Alzheimer's care.
Published 9 Jan 2025
Mayo Clinic-backed, Halle Berry-approved: Pendulum’s Dr. Colleen Cutcliffe is tackling type 2 diabetes before it even starts.
As clinical trials progress, Pendulum hopes their medical evidence can beat the status quo and encourage Americans to take preventative care into their own hands.
Published 7 Jan 2025
From paper to pancreas: how Aspect Biosystems is leading a bioprinting revolution
A recent multi-billion dollar deal with Novo Nordisk in diabetes and obesity, and an injection of significant funding through a $200 million government partnership - Aspect is worth watching as they enter 2025.
Published 6 Jan 2025
Could a single pill crack the code of treating Alzheimer's disease?
By targeting toxic protein clumps in the brain, Dr. Martin Tolar, founder-CEO of Alzheon, aims to outsmart Alzheimer’s decades ahead of symptoms - and reshape global neurology.
Published 2 Jan 2025
enGene injects new hope into the future of bladder cancer care
Ron Cooper, ex-Albireo CEO, is betting on enGene’s novel gene delivery platform to sidestep BCG shortfalls and transform bladder cancer treatment worldwide.
Published 24 Dec 2024
Top Satellite Events at JPM Week
If you're planning to attend JPM Week, here are the top satellite events that should be on your radar.
Published 22 Dec 2024
How Saama’s ‘Clinical-LM’ is Supercharging Global Drug Trials
As drugmakers face mounting complexity and cost in clinical trials, Saama’s AI-driven platform promises swifter, more precise results.
Published 20 Dec 2024
A CRO for biotechs to grow
Allucent is a new CRO with a new CEO on a mission to support young biotechs.
Published 20 Dec 2024
Is a world without eyedrops possible?
SpyGlass Pharma is poised to revolutionize glaucoma treatment by implanting an innovative long-term drug delivery system directly inside the eye. Their treatment promises to continuously release eyedrop medication for 3 years after surgery, as opposed to using eye drops manually every day.
Published 6 Dec 2024
Blood tests for cancer are here and Guardant Health is leading the charge
Guardant Health has seen a string of consistent firsts - most recently FDA approval for colorectal cancer in July, 2024
Published 5 Dec 2024
GERD affects millions of Americans. This drug is the first major innovation in three decades.
GERD affects 65 million Americans, yet innovation in treatment had stagnated. Phathom Pharmaceuticals' FDA approval of VOQUEZNA® (vonoprazan) is a big moment for patients.
Published 5 Dec 2024
Let there Belite: the prospect of an oral pill for vision loss
If left untreated, Stargardt disease and Geographic Atrophy almost always lead to vision loss and blindness - but a groundbreaking oral treatment in the last stage of clinical trials offers new hope.
Published 4 Dec 2024
How ImmunityBio is transforming cancer - a treatment in just 30 seconds
“I think I'm blessed with truly the best team in all of pharma… we are doing something that's bigger than all of us!”
Published 3 Dec 2024
